BioCardia regains Nasdaq compliance; stock continues trading on Capital Market

BioCardia, Inc.

Received Nasdaq notice on Oct 1, 2025 confirming compliance with Listing Rule 5550(b)(1).
Company improved balance sheet and raised new capital to meet equity requirements.
Common stock (BCDA) will continue to trade on Nasdaq Capital Market without interruption.
Resolution removes previous delisting risk associated with equity deficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.